Nymox Pharmaceutical: Assessing The Short And Long Ideas
Avisol Capital Partners, 13 June 2019
Nymox Pharmaceutical (NYMX) has been accused of being an outright serial scam by well-known biopharma short expert Richard Pearson. This was from August 10, 2016, and he had this headline for his article – “Nymox: This Offshore ‘Biotech’ Promotion Will Go To Zero (Yes, Zero).” In that well-written article, he went on to claim how the company hid details of poor trial data from the public, while senior management continued to dump stock without timely SEC disclosure, how the company’s auditor, legal counsel, bankers are all “closely tied to regulatory violations, stock promotions and/or outright fraud,” and how the author filed an SEC complaint against the company after publishing the article.
That article took the stock down by almost 50%. However, it quickly recovered in the same month to soar back to above where it was before the fall. Couple more short articles followed over the years. Some people, I am sure, made money during that fall and rise.
Continue reading “Article: Nymox Pharmaceutical: Assessing The Short And Long Ideas”
